Today: 30 June 2026
Lumentum stock slides 8% in afternoon trade as tech pulls back; Feb. 3 earnings ahead
14 January 2026
1 min read

Lumentum stock slides 8% in afternoon trade as tech pulls back; Feb. 3 earnings ahead

New York, Jan 14, 2026, 13:47 (ET) — Regular session

Lumentum Holdings Inc (LITE.O) shares dropped 8.1% to $331.93 Wednesday afternoon, deepening the pullback for the Nasdaq-listed optical components maker. The stock reached an intraday peak of $363 before sliding to a low of $331.56, starting the day at $354.15.

The slide came amid a broader retreat in tech and growth stocks, with the Invesco QQQ Trust (QQQ) falling 1.7% and the SPDR S&P 500 ETF Trust (SPY) down around 1.0%. Investors were digesting mixed bank earnings alongside fresh U.S. economic figures. “It’s not unusual to see a little bit of a pullback,” said Jake Johnston, deputy CIO at Advisors Asset Management. Eric Diton, managing director at the Wealth Alliance, noted, “We’re due for those 490 stocks to outperform those top 10 huge ones that are tech.” Reuters

Lumentum produces optical and photonic products for cloud and communication networks, as well as lasers for industrial uses. Its cloud and networking segment supplies components and modules for data-center infrastructure, including equipment linked to artificial intelligence workloads.

Shares of other optics and data-center hardware firms also slipped. Coherent lost 3.4%, Ciena dropped 4.5%, Arista Networks slid 4.3%, and Credo Technology took a 5.8% hit; Nvidia declined roughly 2.1%.

Analyst targets are all over the place despite recent updates. The average one-year price target from Fintel ticked up to $298.27, but that’s still a fair bit under the latest close at $361.33. Price estimates vary widely, from as low as $141.40 to as high as $493.50.

That gap puts the stock at risk once appetite for risk fades and investors begin weighing price action against what analysts still have forecasted. In the fast-paced world of AI-related hardware, sentiment often shifts ahead of the actual data.

It works both ways, though. Should the upcoming earnings report show demand settling down, or margins falling short of forecasts, traders who jumped on the rally might start pulling back their positions.

The next key event is set: Lumentum plans to release its fiscal second-quarter 2026 earnings on Feb. 3, right after the market closes. An investor call will follow later that day.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Previous Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Next Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Go toTop